LivaNovaLIVN +0.49%76 PS Ratio is 3.23 as of Jul. 06, 2026, which is 11% above its 10-year median of 2.90. GuruFocus rates LIVN with a GF Score™ of 76/100 and a GF Value™ of $62.57 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, LivaNova ranks worse than 52.8% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, LivaNova's share price is $84.04.
LivaNova's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $26.02. Hence, LivaNova's PS Ratio for today is 3.23.
Warning Sign:
LivaNova PLC stock PS Ratio (=3.21) is close to 3-year high of 3.21.
The historical rank and industry rank for LivaNova's PS Ratio or its related term are showing as below:
LIVN'
s PS Ratio Range Over the Past 10 Years
Min: 1.45 Med: 2.9 Max: 5.78
Current: 3.2
During the past 13 years, LivaNova's highest PS Ratio was 5.78. The lowest was 1.45. And the median was 2.90.
LIVN's PS Ratio is ranked worse than 52.8% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs LIVN: 3.20
LivaNova's Revenue per Sharefor the
three
months ended in Mar. 2026 was $6.48.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $26.02.
During the past 12 months, the average Revenue per Share Growth Rate of LivaNova was 11.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.10% per year.
During the past 13 years, LivaNova's highest 3-Year average Revenue per Share Growth Rate was 183.90% per year. The lowest was -5.20% per year. And the median was 12.85% per year.
Back to Basics: PS Ratio
LivaNova (NAS:LIVN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
LivaNova PS Ratio Related Terms
LivaNova PS Ratio Historical Data
* Premium members only.
The historical data trend for LivaNova's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LivaNova's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's PS Ratio distribution charts can be found below:
* The bar in red indicates where LivaNova's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
LivaNova's Share Price of today is $84.04. LivaNova's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
LivaNova (LIVN) has a PS Ratio of 3.23 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on LivaNova and its competitors. This is 11% above median its historical median of 2.90. Over the past decade, LivaNova's PS Ratio has ranged from 1.45 to 5.78. According to the industry distribution chart, LivaNova ranks #425 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 52.8%.
Is LivaNova's PS Ratio too high?
LivaNova's current PS Ratio of 3.23 is 11% above median its 10-year median of 2.90. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 5.78. The Medical Devices & Instruments industry median PS Ratio is 2.94. LivaNova's value of 3.23 is 9.9% above this industry median. Based on the distribution chart, LivaNova ranks #425 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LivaNova has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's PS Ratio compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #425 out of 805 companies for PS Ratio. This places LivaNova in the lower half of its industry. The industry median PS Ratio is 2.94. LivaNova's value of 3.23 is 9.9% above this benchmark. Historically, LivaNova's own PS Ratio has ranged from 1.45 to 5.78 over the past decade. While the company's 10-year median is 2.90 vs. the industry median of 2.94, LivaNova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LivaNova's current PS Ratio of 3.23 is 9.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on LivaNova and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LivaNova's current PS Ratio is 3.23, which is 11% above median its own 10-year median of 2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $62.57, compared to a current price of $84.04 — trading 34.3% above its estimated fair value. The current PS Ratio is 3.23, which is 11% above median its 10-year median of 2.90 and 9.9% above the Medical Devices & Instruments industry median of 2.94. LivaNova's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For LivaNova (LIVN), the current PS Ratio is 3.23 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LivaNova (LIVN) Overvalued in 2026?
Based on GuruFocus' analysis, LivaNova stock appears to be overvalued.
The current stock price of $84.04 is trading 34.3% above its estimated GF Value™ of $62.57.
GuruFocus considers LivaNova to be Significantly Overvalued.
Key valuation signals for LIVN:
PS Ratio: 3.23 (11% above median its 10-year median of 2.90)
GF Value™: $62.57 vs. price of $84.04 (34.3% above fair value)
Industry Position: 9.9% above the Medical Devices & Instruments median (#425 of 805)
No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
76GF Score
Get the complete analysis for LIVN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIVN has been successfully added to your 
